



NEWS RELEASE

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

2026-05-11

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- **Evolus, Inc.** (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced "esteem"), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market.

The Estyme® collection includes four injectable HA gels that will cover a wide range of applications. The collection includes Estyme® Smooth and Estyme® Form, which are currently marketed in the United States under the brand Evolysse®, along with the debut of two products including Estyme® Lips and the flagship product in the line, Estyme® Sculpt, which is expecting U.S. FDA approval later this year. Developed for restoring mid-face volume, Estyme® Sculpt addresses one of the most in-demand treatment areas in aesthetics. Designed by Symatase, the innovative Cold-X® technology helps preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results.

The commercial launch follows the successful CE Mark certification under the European Medical Device Regulation (MDR), one of the most stringent regulatory frameworks globally, validating the safety, efficacy, and quality of the Estyme® collection.

"With the commercial launch of Estyme®, we are entering a new phase of growth as a multi-product aesthetics company in Europe," said David Moatazedi, President and Chief Executive Officer of Evolus. "We are especially excited to introduce Estyme® Sculpt to practitioners, a product we believe has the potential to become a leader in mid-face volumizing treatments. By pairing this innovative technology with the commercial strength we've built with Nuceiva®, we are uniquely positioned among several companies with a neurotoxin and filler portfolio."

Dr. Benji Dhillon, a prominent UK-based cosmetic surgeon and founder of the Define Clinic, commented, “The launch of Estyme® in Europe is an exciting advancement for practitioners. The Cold-X® technology is designed to preserve the integrity of the hyaluronic acid, which is important when aiming for refined, natural-looking outcomes. Having a versatile range of gels that can be used across different treatment areas gives practitioners greater flexibility and confidence in delivering personalized results for patients.”

Estyme® marks the company’s second commercial aesthetics product internationally, following the successful launch of Nuceiva® starting in 2022. The European launch of Estyme® Sculpt is particularly significant, as it represents the first commercial availability of this mid-face volumizing product globally, ahead of the anticipated U.S. approval of Evolysse® Sculpt later this year.

In addition to Estyme® Sculpt, the Estyme® collection includes three complementary injectable HA gels: Estyme® Form, Estyme® Smooth, and Estyme® Lips. Together, the portfolio provides practitioners with a comprehensive set of products to deliver tailored, natural-looking aesthetic outcomes across multiple indications.

The Estyme® collection, branded as Evolysse® in the U.S., has demonstrated strong clinical performance in U.S. pivotal studies, including non-inferiority and statistical superiority versus a leading comparator in head-to-head studies, reinforcing consistency across Evolus’ global injectable HA gel portfolio¹.

The dermal filler category represents a significant opportunity for Evolus, effectively doubling its addressable market outside the United States and supporting the company’s strategy to become a global, multi-product aesthetics leader².

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on [LinkedIn](#), [X](#), [Instagram](#) or [Facebook](#).

¹ Based on the U.S. pivotal study primary endpoint analysis for Evolysse® Form (95% CI [-0.500, -0.032]) and Evolysse® Smooth (95% CI [-0.416, -0.019]).

² Market data represent internal company estimates and management analysis derived from third-party industry sources, including Decision Resources Group (DRG 2023, DRG 2025) and Business Integration Partners (BIP Q3

2025). Projections are based on management estimates and are subject to change.

Forward-Looking Statements

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future or anticipated events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches; market and revenue growth; the expected benefits of anticipated product launches, regulatory approvals and the company's injectable HA gel portfolio; the company's competitive positioning and market leadership expectations; the company's global commercial expansion strategy; and the anticipated clinical performance and market reception of its products.

The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, our reliance on consumer discretionary spending, unfavorable global economic conditions including trade disputes, tariffs and regulatory actions on imports, uncertainties related to customer and consumer adoption of Jeuveau[®] and Estyme[®]/Evolysse[®], the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse[®] Hyaluronic Acid (HA) gels in the U.S. and Estyme[®] HA gels in Europe, our ability to maintain regulatory approvals of Jeuveau[®] and Evolysse[®] or obtain regulatory approvals for new product candidates or indications, our reliance on Symatase to achieve and/or maintain regulatory approval for the Evolysse[®] HA gel products in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for quarter ended March 31, 2026 filed with the Securities and Exchange Commission on or about May 4, 2026. These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances

or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.

Jeuveau[®], Nuceiva[®], and Evolysse[®] are registered trademarks of Evolus, Inc.

Estyme[®] and Cold-X[®] are registered trademarks of Symatase Aesthetics S.A.S.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus